January 2003

The Impact of a Prostaglandin's First-Line Approval

Glaucoma subspecialists comment on how XALATAN's FDA approval as a first-line treatment affects clinical practice.

ROBERT J. NOECKER, MD; PHILIP P. CHEN, MD; ROBERT D. FECHTNER, MD; AND EVE J. HIGGINBOTHAM, MD

Bimatoprost Monotherapy Lowers IOP More Effectively Than Latanoprost

A look at the results of a 6-month, randomized clinical trial.

ROBERT J. NOECKER, MD

What Can We Learn From OHTS and EMGT?

These clinical trials enable ophthalmologists to base glaucoma management more on evidence than habit.

ROBERT D. FECHTNER, MD, AND PAUL J. LAMA, MD

The Implications of AGIS for Clinical Practice

Harry A. Quigley, MD, describes the insights offered by this study and the potential pitfalls involved in interpreting its results.

GILLIAN MCDERMOTT, EDITOR-IN-CHIEF

Surgically Revising Bleb Leaks After Trabeculectomy

Advice on how to maintain filtration long-term.

MARLENE R. MOSTER, MD, AND AUGUSTO AZUARA-BLANCO, MD, PHD

Selecting Adjunctive Therapy in Glaucoma

Meeting the challenge of IOP control in patients for whom monotherapy has failed.

TONY REALINI, MD

A New Addition for Filtration Surgery

The latest on the Ex-PRESS Mini Glaucoma Shunt.

KARANJIT S. KOONER, MD, MBA

Large Traumatic Cyclodialysis Cleft

JEFFREY D. HENDERER, MD

5 Questions With Theodore Krupin, MD

Theodore Krupin, MD